Հունաստան -
հունարեն -
Εθνικός Οργανισμός Φαρμάκων
rezlod ey.dro.sol 2%
pharmathen international s.a., greece Δερβενακίων 4,, 153 51 153 51, Παλλήνη Αττικής 210.66 66 636 - dorzolamide - ey.dro.sol (ΟΦΘΑΛΜΙΚΕΣ ΣΤΑΓΟΝΕΣ, ΔΙΑΛΥΜΑ) - 2% - dorzolamide 20mg - dorzolamide
Հունաստան -
հունարեն -
Εθνικός Οργανισμός Φαρμάκων
eyopto ey.dro.sol 5mg/ml
ΦΑΡΜΑΤΕΝ ΑΒΕΕ Δερβενακίων 6,, 153 51 153 51, Παλλήνη Αττικής 210.6666636, 6604300 - timolol maleate - ey.dro.sol (ΟΦΘΑΛΜΙΚΕΣ ΣΤΑΓΟΝΕΣ, ΔΙΑΛΥΜΑ) - 5mg/ml - timolol maleate 6,834mg - timolol
Հունաստան -
հունարեն -
Εθνικός Οργανισμός Φαρμάκων
eyopto ey.dro.sol 2,5mg/ml
ΦΑΡΜΑΤΕΝ ΑΒΕΕ Δερβενακίων 6,, 153 51 153 51, Παλλήνη Αττικής 210.6666636, 6604300 - timolol maleate - ey.dro.sol (ΟΦΘΑΛΜΙΚΕΣ ΣΤΑΓΟΝΕΣ, ΔΙΑΛΥΜΑ) - 2,5mg/ml - timolol maleate 3,417mg - timolol
Եվրոպական Միություն -
հունարեն -
EMA (European Medicines Agency)
xeljanz
pfizer europe ma eeig - tofacitinib - Αρθρίτιδα, ρευματοειδή - Ανοσοκατασταλτικά - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 και 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.
Կիպրոս -
հունարեն -
Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
amesol 250mg film coated tablets
medochemie ltd (0000003169) 1-10 constantinoupoleos str, lemesos, 3011, 51409 (3505) - levofloxacin hemihydrate - film coated tablets - 250mg - levofloxacin hemihydrate (8000003372) 256mg - levofloxacin
Կիպրոս -
հունարեն -
Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
amesol 500mg film coated tablets
medochemie ltd (0000003169) 1-10 constantinoupoleos str, lemesos, 3011, 51409 (3505) - levofloxacin hemihydrate - film coated tablets - 500mg - levofloxacin hemihydrate (8000003372) 512mg - levofloxacin
Կիպրոս -
հունարեն -
Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
asacol 4g/100ml enema
tillotts pharma gmbh (0000010051) warmbacher str. 80, rheinfelden, 79618 - mesalazine - enema - 4g/100ml - mesalazine (0000089576) 4g - mesalazine